

BD Breaks Ground on High-Tech Manufacturing Facility in Zaragoza, Spain to Support Growth of Pre-Filled Drug Delivery

New facility will expand BD's capacity to supply the European market with pre-fillable syringes for use in applications such as vaccines and other biologic drugs; add 150 local jobs by 2024.

FRANKLIN LAKES, N.J. (November 16, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, broke ground on a €165 million (\$200 million USD) manufacturing facility in the city of Zaragoza, located in the Aragon region of Spain.

The new site, which will initially encompass 8,000 square meters (86,000 square feet), is estimated to open in late 2023. BD is beginning its recruitment process to fill key positions supporting the design and set-up of this site, including engineers, technicians, and other key support staff. Open roles can be found at <https://emea.jobs.bd.com/location/spain-jobs/28892/2510769/2>.

"These roles will be on the front lines of building a sustainable, state-of-the-art and fully digital site incorporating the latest in intelligent and autonomous solutions," said Thibault Naegelen, program director for BD's Zaragoza facility. "We look forward to building a team in Zaragoza that helps BD meet its mission of advancing the world of health by supplying our European customers with devices that enhance drug delivery."

BD's Zaragoza team will produce drug delivery devices, primarily for biopharmaceutical companies that supply the European market with drugs in pre-fillable syringes such as vaccines and other biologic drugs. The new plant will add needed capacity to support major vaccination campaigns going forward, such as the one currently taking place for the COVID-19 pandemic.

"Pre-fillable drug systems are a known factor in helping health care providers effectively, reliably and consistently administer drug therapies," said Eric Borin, worldwide president of BD Pharmaceutical Systems. "Today, more than 70 percent of the top 100 biopharmaceutical companies rely on BD pre-fillable syringes. This groundbreaking marks an important milestone in our ability to extend manufacturing capacity for our customers as they continue to grow their vaccine and biologic drug pipelines."

BD will also be hiring operators and production staff to oversee the production lines closer to the site's opening date in 2023. The site will meet high sustainability and eco-efficiency standards. By 2030, the site is expected to employ up to 600 people with an area of 30,000 square meters (323,000 square feet).

The new site is part of the [\\$1.2 billion, four-year USD investment that was announced in late 2020](#) to expand and upgrade BD's manufacturing capacity and technology for pre-fillable syringes and advanced drug delivery systems as part of the company's 2025 growth strategy. The Zaragoza facility will mark BD's fourth facility in Spain, where it currently has three production plants employing approximately 1,500 employees: San Agustín de Guadalix, Fraga and Almaraz.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter [@BDandCo](https://twitter.com/BDandCo).

Contacts:

Media:

Investors:

Trey Hollern Nadia Goncalves
BD Public Relations BD Investor Relations

862.284.8629 201.847.5934
trey.holtern@bd.com nadia.goncalves@bd.com

<https://news.bd.com/2021-11-16-BD-Breaks-Ground-on-High-Tech-Manufacturing-Facility-in-Zaragoza,-Spain-to-Support-Growth-of-Pre-Filled-Drug-Delivery>